BioNTech and Pfizer has said that a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test.
BioNTech and Pfizer could deliver an Omicron-based vaccine in March 2022 if needed.
BioNTech and Pfizer said that two vaccine doses resulted in significantly lower neutralising antibodies but that a third dose of their vaccine increased the neutralising antibodies by a factor of 25.
The companies said they would continue their effort to bring an Omicron-specific COVID-19 vaccine to market.
However, a lab analysis at the university hospital of Frankfurt, Germany found a reduced antibody response to Omicron even after three shots.